NO953862L - Fremgangsmåte for å redusere viskositeten i luftveienes patologiske mucusinnhold i den respiratoriske trakt - Google Patents

Fremgangsmåte for å redusere viskositeten i luftveienes patologiske mucusinnhold i den respiratoriske trakt

Info

Publication number
NO953862L
NO953862L NO953862A NO953862A NO953862L NO 953862 L NO953862 L NO 953862L NO 953862 A NO953862 A NO 953862A NO 953862 A NO953862 A NO 953862A NO 953862 L NO953862 L NO 953862L
Authority
NO
Norway
Prior art keywords
contents
actin
respiratory tract
viscosity
pathological
Prior art date
Application number
NO953862A
Other languages
English (en)
Norwegian (no)
Other versions
NO953862D0 (no
Inventor
Thomas P Stossel
Stuart Lind
Paul A Janmey
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of NO953862L publication Critical patent/NO953862L/no
Publication of NO953862D0 publication Critical patent/NO953862D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO953862A 1993-04-02 1995-09-29 Fremgangsmåte for å redusere viskositeten i luftveienes patologiske mucusinnhold i den respiratoriske trakt NO953862D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/042,247 US5464817A (en) 1990-04-11 1993-04-02 Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
PCT/US1994/003667 WO1994022465A1 (fr) 1993-04-02 1994-04-04 Procede de reduction de la viscosite de mucosites pathologiques presentes dans les voies respiratoires

Publications (2)

Publication Number Publication Date
NO953862L true NO953862L (no) 1995-09-29
NO953862D0 NO953862D0 (no) 1995-09-29

Family

ID=21920852

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953862A NO953862D0 (no) 1993-04-02 1995-09-29 Fremgangsmåte for å redusere viskositeten i luftveienes patologiske mucusinnhold i den respiratoriske trakt

Country Status (17)

Country Link
US (2) US5464817A (fr)
EP (1) EP0692970B1 (fr)
JP (2) JPH08510998A (fr)
KR (1) KR100308679B1 (fr)
CN (1) CN1107521C (fr)
AT (1) ATE182790T1 (fr)
AU (1) AU695033B2 (fr)
BR (1) BR9405856A (fr)
CA (1) CA2159205A1 (fr)
DE (1) DE69419907T2 (fr)
DK (1) DK0692970T3 (fr)
ES (1) ES2135576T3 (fr)
GB (1) GB2293102B (fr)
GR (1) GR3031753T3 (fr)
NO (1) NO953862D0 (fr)
SG (1) SG49574A1 (fr)
WO (1) WO1994022465A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
US5593964A (en) * 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
SK284191B6 (sk) * 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
ATE230027T1 (de) * 1995-02-24 2003-01-15 Genentech Inc Menschliche dnase i varianten
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
PT854927E (pt) * 1995-10-10 2008-09-08 Genentech Inc Variantes da adnase i humana
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
EP0941108B1 (fr) * 1996-12-04 2002-10-16 Renovo Limited Guerison de blessures et traitement de la fibrose
EP1249244A1 (fr) * 2001-04-13 2002-10-16 Universiteit Gent Compositions thérapeutiques pour le traitement d'une maladie influencée par l'équilibre G-actin / F-actin, p.e. une maladie respiratoire
EP1459758B1 (fr) * 2001-12-28 2009-02-25 Asubio Pharma Co., Ltd. Cofiline favorisant la proliferation et/ou la differenciation de cellules souches hematopoietiques et/ou de precurseurs hematopoietiques
WO2005004904A1 (fr) * 2003-07-14 2005-01-20 Dmitry Dmitrievich Genkin Methode de traitement de maladies s'accompagnant d'alterations de la composition qualitative et/ou quantitative de l'adn extracellulaire du sang (variantes)
US8431123B2 (en) * 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
WO2005046454A2 (fr) * 2003-11-12 2005-05-26 Trustrees Of The University Of Pennsylvania Procedes d'utilisation de la gelsoline pour traiter ou prevenir la sepsie bacterienne
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US8518457B2 (en) * 2004-05-11 2013-08-27 Pulmonox Technologies Corporation Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
KR101314461B1 (ko) * 2004-05-12 2013-10-07 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
EP1791566A4 (fr) * 2004-08-06 2008-07-16 Nat Jewish Med & Res Center Produit et procede permettant d'empecher le developpement d'un film biologique
US8916151B2 (en) * 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
PT3279663T (pt) 2006-03-15 2021-09-24 Brigham & Womens Hospital Inc Utilização de gelsolina para o diagnóstico e tratamento de doenças inflamatórias
DK2002258T3 (en) * 2006-03-15 2018-01-02 Brigham & Womens Hospital Inc APPLICATION OF GELSOLINE TO TREAT MULTIPLE SCLEROSIS AND DIAGNOSTICATION OF NEUROLOGICAL DISEASES
PL2095825T3 (pl) * 2006-11-28 2011-12-30 Cls Therapeutics Ltd Sposób leczenia ludzkich chorób związanych ze zwiększoną zawartością kwasu deoksyrybonukleinowego w przestrzeniach pozakomórkowych i tkankach i preparat leczniczy do przeprowadzenia tego sposobu
US8753662B2 (en) * 2007-02-15 2014-06-17 National Jewish Health Methods and compositions for the disruption of biofilms
ES2634263T3 (es) * 2008-01-25 2017-09-27 The General Hospital Corporation Usos de diagnóstico terapéuticos de gelsolina en insuficiencia renal
US20150010527A1 (en) 2012-02-01 2015-01-08 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
RU2726131C2 (ru) 2015-05-22 2020-07-09 Дмитрий Дмитриевич Генкин Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
KR20200122320A (ko) 2018-01-16 2020-10-27 씨엘에스 테라퓨틱스 리미티드 데옥시리보뉴클레아제 (dnase) 활성을 갖는 효소의 간 발현에 의한 질환의 치료

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
ATE171625T1 (de) * 1990-04-11 1998-10-15 Brigham & Womens Hospital Therapeutische verwendung von actin-bindenden verbindungen
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis

Also Published As

Publication number Publication date
CA2159205A1 (fr) 1994-10-13
KR100308679B1 (ko) 2001-11-30
AU6625094A (en) 1994-10-24
ES2135576T3 (es) 1999-11-01
BR9405856A (pt) 1996-03-05
GR3031753T3 (en) 2000-02-29
EP0692970A1 (fr) 1996-01-24
US5464817A (en) 1995-11-07
US5656589A (en) 1997-08-12
GB2293102A (en) 1996-03-20
GB9520020D0 (en) 1995-12-06
WO1994022465A1 (fr) 1994-10-13
CN1122108A (zh) 1996-05-08
EP0692970B1 (fr) 1999-08-04
DE69419907D1 (de) 1999-09-09
JPH08510998A (ja) 1996-11-19
JP2001302537A (ja) 2001-10-31
SG49574A1 (en) 1998-06-15
AU695033B2 (en) 1998-08-06
NO953862D0 (no) 1995-09-29
DK0692970T3 (da) 1999-12-06
ATE182790T1 (de) 1999-08-15
DE69419907T2 (de) 1999-12-09
GB2293102B (en) 1996-10-09
CN1107521C (zh) 2003-05-07

Similar Documents

Publication Publication Date Title
NO953862D0 (no) Fremgangsmåte for å redusere viskositeten i luftveienes patologiske mucusinnhold i den respiratoriske trakt
DK1094834T3 (da) Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf
DK0754048T3 (da) Behandling af partielt væksthormon-insentivitetssyndrom
DE69130289D1 (de) Therapeutische verwendung von actin-bindenden verbindungen
BR9608449A (pt) Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica.
BR9809951A (pt) Método para tratamento da obesidade
BR9607601A (pt) Uso de ácido hialurÈnico para o tratamento de cistite intersticial
PT782630E (pt) Gene da doenca poliquistica do rim
PT914148E (pt) Tratamento do sindroma de insensibilidade parcial a hormona de crescimento
BR9909180A (pt) Utilização de pelo menos um fragmento de uma proteìna de membrana e processo de prepração de uma proteìna ou um de seus fragmentos por via recombinante
NZ334762A (en) Human DNase I variants having binding affinity to actin
BR9510323A (pt) Variante de dnase i humana ácido nucleico isolado método para tratamento de um paciente tendo uma desordem ou doença pulmonar e composição farmacêutica
Kurowski et al. Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti-digitalis antibodies
BR0011178A (pt) Molécula sintética biologicamente ativa, método para sua preparação e medicamento baseado na mesma
ATE267612T1 (de) Verwendung von vogel-antikörpern
BR9713355A (pt) Proteìna de ligação à lactoferrina d streptococcus uberis
Sheppard et al. PHI and NPY in the lung innervation
Shaw et al. The effect of gastric surgery on intact neurotensin (NT) response to a fatty meal
Kobori et al. Immunohistological observation of the Cochlea Using the Serum from the Patient with Relapsing Polychondritis
Garay Azelastine: Well known ciliotoxic agent?
李建福 et al. Changes of bioelectric potentials of experimental fracture healed under compressive external fixation
Saxena et al. The role of the female Syrian hamster protein on the interaction between serum lipoproteins and heparin
NO952608L (no) Derivatiserte kalsitoniner
ES2183376T3 (es) Uso de lbp para el tratamiento de la septicemia.
MX9703191A (es) Anticuerpos contra proteinas alogenicas y xenogenicas, su uso en diagnostico y terapia y metodos para la determinacion de los mismos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application